Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (271-280 of 399) with videos related to

Pageof 40
Sort By:
Hypertension (Dallas, Tex. : 1979)|March 18, 2015
AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathyChristine Koulis, Bryna S M Chow, Maria McKelvey, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|September 23, 2022
Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR DeclineChunmei Qin, Yiting Wang, Lijun Zhao, et al.
Cardiovascular Diabetology. Endocrinology Reports|April 1, 2026
Effects of empagliflozin on cardiac function and cardiorespiratory fitness in people with type 2 diabetes: a randomised controlled trialNatalie Nanayakkara, Michael L H Huang, Andre La Gerche, et al.
Hypertension (Dallas, Tex. : 1979)|June 3, 2011
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialYan Miao, Stefan A Ottenbros, Goos D Laverman, et al.
Diabetes|September 9, 2010
Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mousePhyllis Chew, Derek Y C Yuen, Nada Stefanovic, et al.
Clinical Science (London, England : 1979)|April 15, 2014
Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosisChristine Koulis, Peter Kanellakis, Raelene J Pickering, et al.
Journal of Diabetes|December 22, 2020
Combining glomerular basement membrane and tubular basement membrane assessment improves the prediction of diabetic end-stage renal diseaseLijun Zhao, Junlin Zhang, Song Lei, et al.
Circulation Research|March 8, 2003
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changesRiccardo Candido, Josephine M Forbes, Merlin C Thomas, et al.
Diabetes|October 26, 2007
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathwayVicki Thallas-Bonke, Suzanne R Thorpe, Melinda T Coughlan, et al.
Kidney International|May 20, 2003
Reduced tubular cation transport in diabetes: prevented by ACE inhibitionMerlin C Thomas, Chris Tikellis, Wendy C Burns, et al.
Pageof 40

Showing results (271-280 of 399) with videos related to

Sort By:
Pageof 40
Hypertension (Dallas, Tex. : 1979)|March 18, 2015
AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathyChristine Koulis, Bryna S M Chow, Maria McKelvey, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|September 23, 2022
Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR DeclineChunmei Qin, Yiting Wang, Lijun Zhao, et al.
Cardiovascular Diabetology. Endocrinology Reports|April 1, 2026
Effects of empagliflozin on cardiac function and cardiorespiratory fitness in people with type 2 diabetes: a randomised controlled trialNatalie Nanayakkara, Michael L H Huang, Andre La Gerche, et al.
Hypertension (Dallas, Tex. : 1979)|June 3, 2011
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialYan Miao, Stefan A Ottenbros, Goos D Laverman, et al.
Diabetes|September 9, 2010
Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mousePhyllis Chew, Derek Y C Yuen, Nada Stefanovic, et al.
Clinical Science (London, England : 1979)|April 15, 2014
Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosisChristine Koulis, Peter Kanellakis, Raelene J Pickering, et al.
Journal of Diabetes|December 22, 2020
Combining glomerular basement membrane and tubular basement membrane assessment improves the prediction of diabetic end-stage renal diseaseLijun Zhao, Junlin Zhang, Song Lei, et al.
Circulation Research|March 8, 2003
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changesRiccardo Candido, Josephine M Forbes, Merlin C Thomas, et al.
Diabetes|October 26, 2007
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathwayVicki Thallas-Bonke, Suzanne R Thorpe, Melinda T Coughlan, et al.
Kidney International|May 20, 2003
Reduced tubular cation transport in diabetes: prevented by ACE inhibitionMerlin C Thomas, Chris Tikellis, Wendy C Burns, et al.
Pageof 40